

# Evolution of clotting factor consumption over the last fifteen years for ambulatory hemophilia patients in a French comprehensive care center

F. Bel<sup>(1)(2)</sup>; A. Lienhart<sup>(1)</sup>; S. Meunier<sup>(1)</sup>; C. Negrier<sup>(1)</sup>; V. Chamouard<sup>(1)(2)</sup>  
<sup>(1)</sup> Hemophilia Treatment Center – Hôpital Louis Pradel – Hospices Civils de Lyon – Bron, France  
<sup>(2)</sup> Pharmacy – Groupement Hospitalier Est – Hospices Civils de Lyon – Bron, France

## Introduction :

Analysis of clotting factors concentrate (CFC) consumption  
 → information about treatment strategies in our care center.

## Objectives :

Assess practice and CFC consumption at a hemophilia care center over 15 years



## Methods :

- Retrospective monocenter study
- CFC ambulatory consumption in hemophilia A and B from January 2001 to December 2015
- Collect of patients' characteristics and treatment details

## Results :

From 2001 to 2015	FVIII	FIX
Global consumption evolution (IU)	+ 147 %	+ 320 %
Part of recombinant factors	76 % to 91 %	28 % to 52 %

Prophylactic treatment		2001 → 2005	2011 → 2015
Cohort of severe patients under 12 years	HA	39 %	83 %
	HB	38 %	87 %
Prophylactic treatment		2001 → 2005	2011 → 2015
Cohort of adults	HA	34 %	51 %
	HB	28 % (stable)	



In 2015	
FVIII	FIX
19.5M IU	5.5M IU
14M €	4M €
142 HA (3% of the french hemophilia patients' cohort)	55 HB (5% of the french hemophilia patients' cohort)

FVIII consumption during the study period in our center  
 → growth of more than 10 % per year  
 → representative of the French market

## Conclusions :

- Actual current medical practice favors **primary prophylactic treatment for children** → increase of the total cost of care but at the same time **clinical efficiency** and patients' **quality of life** are improve.
- FVIII and FIX increase illustrate the impact of **prophylaxis** and the need for higher doses of rFVII or rFIX IU to be injected.
- This analysis is an exhaustive review of CFC consumption before availability of **long-acting factors**.

